CymaBay Therapeutics Inc (NASDAQ:CBAY) Director Kurt Von Emster sold 90,098 shares of the business’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $12.15, for a total transaction of $1,094,690.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Kurt Von Emster also recently made the following trade(s):

  • On Wednesday, January 31st, Kurt Von Emster sold 97,639 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $12.22, for a total transaction of $1,193,148.58.
  • On Thursday, January 25th, Kurt Von Emster sold 39,438 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $12.18, for a total transaction of $480,354.84.
  • On Monday, January 22nd, Kurt Von Emster sold 138,253 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $10.40, for a total transaction of $1,437,831.20.
  • On Friday, January 19th, Kurt Von Emster sold 144,216 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $10.25, for a total transaction of $1,478,214.00.
  • On Friday, January 5th, Kurt Von Emster sold 4,300 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $10.21, for a total transaction of $43,903.00.
  • On Friday, December 22nd, Kurt Von Emster sold 173,192 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $9.41, for a total transaction of $1,629,736.72.
  • On Friday, November 10th, Kurt Von Emster sold 50,048 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $9.26, for a total transaction of $463,444.48.

CymaBay Therapeutics Inc (NASDAQ CBAY) opened at $11.79 on Wednesday. The firm has a market cap of $517.16, a P/E ratio of -11.67 and a beta of 2.04. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.39 and a current ratio of 7.39. CymaBay Therapeutics Inc has a 12-month low of $1.92 and a 12-month high of $12.60.

CymaBay Therapeutics (NASDAQ:CBAY) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). During the same quarter in the previous year, the business earned ($0.25) EPS. equities research analysts predict that CymaBay Therapeutics Inc will post -0.87 EPS for the current year.

A number of hedge funds have recently made changes to their positions in the business. Perceptive Advisors LLC acquired a new position in CymaBay Therapeutics during the third quarter valued at approximately $18,948,000. Vanguard Group Inc. lifted its position in shares of CymaBay Therapeutics by 20.7% during the second quarter. Vanguard Group Inc. now owns 991,633 shares of the biopharmaceutical company’s stock worth $5,712,000 after purchasing an additional 170,126 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of CymaBay Therapeutics during the third quarter worth $5,159,000. EAM Investors LLC acquired a new position in shares of CymaBay Therapeutics during the third quarter worth $4,788,000. Finally, Omega Fund Management LLC lifted its position in shares of CymaBay Therapeutics by 82.9% during the third quarter. Omega Fund Management LLC now owns 551,477 shares of the biopharmaceutical company’s stock worth $4,445,000 after purchasing an additional 250,000 shares in the last quarter. 54.70% of the stock is currently owned by hedge funds and other institutional investors.

CBAY has been the subject of a number of recent analyst reports. Piper Jaffray Companies restated a “buy” rating and issued a $12.00 target price on shares of CymaBay Therapeutics in a report on Friday, October 27th. Oppenheimer set a $15.00 target price on shares of CymaBay Therapeutics and gave the company a “buy” rating in a report on Monday, October 30th. Cantor Fitzgerald restated a “buy” rating and issued a $16.00 target price on shares of CymaBay Therapeutics in a report on Wednesday, November 8th. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of CymaBay Therapeutics in a report on Tuesday, November 28th. Finally, Leerink Swann restated a “buy” rating and issued a $16.00 target price on shares of CymaBay Therapeutics in a report on Tuesday, November 28th. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $16.56.

WARNING: “CymaBay Therapeutics Inc (CBAY) Director Sells $1,094,690.70 in Stock” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at https://www.dailypolitical.com/2018/02/07/cymabay-therapeutics-inc-cbay-director-sells-1094690-70-in-stock.html.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Insider Buying and Selling by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.